

# Estradiol

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application. The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Section: [18. Medicines for endocrine disorders](#) > [18.3. Estrogens](#)

ATC codes: [G03CA03](#)

Indication	Hypopituitarism <a href="#">ICD11 code: 5A61.0</a>
INN	Estradiol
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid > tablet: 0.5 mg ; 1 mg ; 2 mg
EML status history	Application rejected in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . <a href="#">↗</a>
Wikipedia	<a href="#">Estradiol</a> <a href="#">↗</a>
DrugBank	<a href="#">Estradiol</a> <a href="#">↗</a>

## Summary of evidence and Expert Committee recommendations

The Expert Committee did not recommend inclusion of 17- $\beta$ -estradiol on the complementary list of the EML for the management of pubertal development in adolescents with primary or secondary ovarian failure. The Committee considered that the application reported insufficient information on the evidence supporting the use of estradiol for the proposed indication, including optimal dosages and formulations. The Committee noted that global prevalence of primary ovarian failure or primary ovarian insufficiency varies among different populations but is generally low. The Committee considered that re-evaluation of estradiol should be made considering additional indications for which estradiol is routinely used, such as hormone replacement therapy in menopause or following hysterectomy.

